Elsevier

Respiratory Medicine

Volume 88, Issue 6, July 1994, Pages 465-468
Respiratory Medicine

Chronic necrotizing pulmonary aspergillosis and pulmonary phycomycosis in cystic fibrosis

https://doi.org/10.1016/S0954-6111(05)80051-4Get rights and content

First page preview

First page preview
Click to open first page preview

References (9)

There are more references available in the full text version of this article.

Cited by (22)

  • The development of pulmonary aspergillosis and its histologic, clinical, and radiologic manifestations

    2018, Clinical Radiology
    Citation Excerpt :

    Patients may be asymptomatic, but typically present with an insidious history of cough (which may be productive), fever, and non-specific constitutional symptoms. The susceptible host is classically mildly immunosuppressed (e.g., diabetes mellitus, alcoholism, steroids) or has a pre-existing parenchymal disease, e.g., old tuberculosis (TB) cavity, although CPA as a differential should not be discarded in seemingly well patients.12,13 Recognition of CPA is essential for the radiologist as they may be the first person to direct the clinician towards the diagnosis.

  • Chronic necrotizing pulmonary aspergillosis presenting as transient migratory thoracic mass: A diagnostic dilemma

    2016, Respiratory Medicine Case Reports
    Citation Excerpt :

    CNPA also called semi-invasive or subacute invasive aspergillosis, is an indolent, cavitary infectious process in the lung parenchymasecondary to local invasion by Aspergillus spp., usually Aspergillus fumigatus, with a slowly progressive clinical course [1]. It is an uncommon manifestation of aspergillosis and usually affects in middle aged and elderly individuals with altered local defenses, associated with underlying chronic lung diseases such as chronic obstructive pulmonary disease (COPD), previous pulmonary tuberculosis, thoracic surgery, radiation therapy, pneumoconiosis, cystic fibrosis, lung infarction or sarcoidosis [2]. It may also occur in patients who are mildly immunocompromised due to DM, alcoholism, chronic liver disease, prolonged low-dose corticosteroid therapy, malnutrition, or connective tissue diseases such as rheumatoid arthritis and ankylosing spondylitis [3].

  • Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases

    2010, International Journal of Infectious Diseases
    Citation Excerpt :

    More than 95% of the patients were positive for Aspergillus antibody, and 81% of them were culture-positive for Aspergillus. These cases do not differ greatly in their clinical features from those reported elsewhere.1,2,6,12–16 Antifungal therapy is the treatment mainstay for patients diagnosed with CNPA.

  • Aspergillus-related lung disease

    2008, Respiratory Medicine CME
    Citation Excerpt :

    The term chronic cavitary pulmonary aspergillosis (CCPA) has been applied to the formation and expansion of multiple pulmonary cavities.86 It was found that these patients usually are middle-aged with evidence of generalized immunosuppression in the form of diabetes mellitus, malnutrition, corticosteroid or radiation therapy, collagen vascular diseases or underlying lung diseases.87,88 These patients usually present with fever, cough, sputum production, and weight loss for several months, but some patients may be asymptomatic.87

  • The clinical spectrum of pulmonary aspergillosis

    2002, Chest
    Citation Excerpt :

    The former, in contrast to the latter, is a chronic process that progresses slowly over months to years, and there is no vascular invasion or dissemination to other organs.40 CNA is usually seen in middle-aged and elderly patients with documented or suspected underlying lung diseases like COPD, inactive tuberculosis, previous lung resection, radiation therapy, pneumoconiosis, cystic fibrosis, lung infarction, or, rarely, sarcoidosis.43 It also has been described in patients with mild immunosuppression, including those with diabetes mellitus, those with poor nutrition, those undergoing low-dose corticosteroid therapy, and those with connective tissue diseases such as rheumatoid arthritis and ankylosing spondylitis.40

View all citing articles on Scopus
View full text